SCHEMBL7218136

SCHEMBL7218136

CCCOc1ccc(COc2ccc3c(c2)C=C(C(=O)Nc2ccc(CN(C)C4CCOCC4)cc2)CCS3(=O)=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.49
CCR5 P51681 7/20 0.43
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 3/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.35
MCL1 Q07820 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.34
CXCR3 P49682 3/20 0.34
CCR7 P32248 2/20 0.34
CXCR5 P32302 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216664 0.96 CCR2 (0.47) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7166194 0.95 CCR2 (0.49) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7165818 0.95 CCR2 (0.49) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7167251 0.94 CCR2 (0.47) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7216597 0.94 CCR2 (0.48) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7221572 0.94 CCR2 (0.49) CCR2CCR5L3MBTL1RAB9AMAPT
SCHEMBL7171409 0.94 CCR2 (0.51) CCR2CCR5RAB9AMAPTALDH1A1
SCHEMBL7221638 0.94 CCR2 (0.49) CCR2CCR5L3MBTL1CXCR3CCR7
SCHEMBL3031528 0.93 CCR2 (0.58) CCR2CCR5L3MBTL1CXCR3CCR7
SCHEMBL30227218 0.93 CCR2 (0.58) CCR2CCR5L3MBTL1CXCR3CCR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US claimed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP claimed
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed